Clinical Trials Sponsored by Researched Nutritionals LLC

Total 1866 results

Janssen Research & Development, LLC

Completed

A Study of JNJ-61393215 in the Treatment of Depression

Major Depressive Disorder With Anxious Distress

United States, Moldova, Republic of, Russian Federation, Ukraine, United Kingdom
Janssen Research & Development, LLC

Completed

A Study of Nipocalimab in Healthy Male and Female Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression

Depressive Disorder, Major

United States, Germany, Moldova, Republic of, Russian Federation, Ukraine, United Kingdom
Janssen Research & Development, LLC

Terminated

An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum

Alzheimer Disease

France, Spain, Netherlands, Belgium, Germany, Sweden
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States
Janssen Research & Development, LLC

Terminated

A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection (PRIMROSE)

Respiratory Syncytial Virus

United States, Germany, Italy, Ukraine, Spain, Sweden, Thailand, Argentina, Bulgaria, Japan, Poland, Canada, Hungary, South Africa
Janssen Research & Development, LLC

Completed

A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH) (CIPHER)

Hypertension, Pulmonary

United States, Belgium, United Kingdom, Spain, Germany, France, Poland, Ukraine, Netherlands
Janssen Research & Development, LLC

Completed

A Study of JNJ-64281802 in Healthy Adult Participants

Healthy

Netherlands
Janssen Research & Development, LLC

No longer available

Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults

Diabetes Mellitus, Type 1

United States
Janssen Research & Development, LLC

Completed

A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder

Depressive Disorder, Major

Belgium, Germany
Janssen Research & Development, LLC

Completed

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

Prostate Neoplasms

Canada, France, Poland, Ukraine, United Kingdom, China, Belgium, Spain, Argentina, Colombia, Israel, Mexico, Portugal, Bulgaria, Germany, Malaysia, Romania, South Africa, Turkey, Korea, Republic of, Japan, Australia, Netherlands, Sweden, New Zealand and more
Janssen Research & Development, LLC

Completed

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]-JNJ-70099731 in Healthy Male Participants

Healthy

Belgium
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure (CHIEF-HF)

Heart Failure

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UNIFI)

Inflammatory Bowel Diseases | Colitis, Ulcerative

United States, Australia, France, Poland, Ukraine, United Kingdom, Belgium, Germany, Israel, Bulgaria, Romania, Serbia, Japan, Canada, Netherlands, Korea, Republic of, New Zealand, Russian Federation, Austria, Hungary, Slovakia, D... and more
Janssen Research & Development, LLC

Completed

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Myelodysplastic Syndromes

United States, Belgium, Italy, Spain, Netherlands, Russian Federation
Janssen Research & Development, LLC

Completed

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis

Arthritis, Psoriatic

United States, Turkey, Malaysia, Czechia, Bulgaria, Poland, Russian Federation, Ukraine, Spain, Taiwan, Latvia, Estonia, Lithuania
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease

Alzheimer Disease

Belgium, Spain, Netherlands, Germany
Janssen Research & Development, LLC

Completed

A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Terminated

A Study of JNJ-53718678 in Participants With Hepatic Impairment

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effects of Loperamide (JNJ-289679) on Electrocardiogram Intervals in Healthy Adult Participants

Healthy Participants

Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on Rilematovir

Healthy

Belgium
Janssen Research & Development, LLC

Withdrawn

A Study of Guselkumab in Adult Participants With Celiac Disease

Celiac Disease

United States
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-70075200 in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of JNJ-64300535 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain

Alzheimer Disease

Belgium
Janssen Research & Development, LLC

Completed

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age (CADMUS Jr)

Psoriasis

United States, Germany, Taiwan, Belgium, Korea, Republic of, Canada, Poland, Hungary, Netherlands
Janssen Research & Development, LLC

Completed

A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy

Dementia | Alzheimer Disease

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression (TRANSFORM-3)

Depressive Disorder, Treatment-Resistant

United States, France, Belgium, Spain, Poland, Bulgaria, South Africa, Finland, Brazil, Sweden, United Kingdom, Lithuania
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease (DUET)

Crohn Disease

United States
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants

Healthy

China
Janssen Research & Development, LLC

Completed

Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States, Spain
Janssen Research & Development, LLC

Completed

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (Aspire II)

Depressive Disorder, Major

United States, Belgium, Canada, Poland, France, Spain, Brazil, Lithuania, Czechia, Austria, Argentina, Turkey
Janssen Research & Development, LLC

Completed

A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vialed Product in Healthy Participants

Healthy

Germany
Consano Clinical Research, LLC

Completed

Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants

Renal Insufficiency

United States
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1)

Psoriasis

United States, Australia, Taiwan, Germany, Spain, Korea, Republic of, Canada, Russian Federation, Poland, Hungary
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (NOVA)

Hidradenitis Suppurativa

United States, France, Canada, Germany, Netherlands, Denmark
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

Influenza A

United States, France, Korea, Republic of, Taiwan, China, India, Argentina, Israel, Thailand, Vietnam, Hungary, Germany, South Africa, Spain, Turkey, Belgium, Brazil, Canada, Mexico, New Zealand, Bulgaria, Peru, Malaysia, Italy, Estonia, ... and more
ParaPRO LLC
Concentrics Research

Completed

Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

Scabies

United States
ParaPRO LLC
Concentrics Research

Completed

Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

Scabies

United States
Janssen Research & Development, LLC

Completed

A Study of the Relationship of Psychosocial Function With Mood Symptoms in Offspring of Parents With Bipolar Disorder

Bipolar Disorder

United States
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-64304500 in Participants With Alopecia Areata

Alopecia Areata

United States, Japan, France, Australia
Janssen Research & Development, LLC

Completed

Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59

Dry Age-related Macular Degeneration

United States
Janssen Research & Development, LLC

Completed

A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-73763989 in Healthy Chinese Adult Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Pharmacokinetic Study of MABp1 in Healthy Volunteers

Healthy

United States

3

Subscribe